Pharmaceutical preparations company · DE · FY ends Dec · Revenue $232M · 17.56% margin · $4M FCF
Margins and capital returns are both well above average: 20.42% operating margin, ROIC at 76.91%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 157.0% YoY with margins expanding 146.3pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$232M
▲ +157.0% YoY
Net Income (TTM)
-$27M
▲ +90.9% YoY
Op. Margin
17.56%
▲ +146.3pp YoY
ROIC
203.99%
▲ +171.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▲ +114.5% YoY
Op. Cash Flow (TTM)
$4M
▲ +114.6% YoY
Net Debt
-$286M
Net Cash Position
Cash & Equiv.
$286M
5Y CAGR: +25.6%
Continue Research